Read by QxMD icon Read

Dengue vaccine

Tiago Souza Salles, Thayane da Encarnação Sá-Guimarães, Evelyn Seam Lima de Alvarenga, Victor Guimarães-Ribeiro, Marcelo Damião Ferreira de Meneses, Patricia Faria de Castro-Salles, Carlucio Rocha Dos Santos, Ana Claudia do Amaral Melo, Marcia Regina Soares, Davis Fernandes Ferreira, Monica Ferreira Moreira
Dengue virus (DENV), an arbovirus transmitted by mosquitoes, has become a major threat to American human life, reaching approximately 23 million cases from 1980 to 2017. Brazil is among the countries most affected by this terrible viral disease, with 13.6 million cases. DENV has four different serotypes, DENV1-4, which show a broad clinical spectrum. Dengue creates a staggering epidemiological and economic burden for endemic countries. Without a specific therapy and with a commercial vaccine that presents some problems relative to its full effectiveness, initiatives to improve vector control strategies, early disease diagnostics and the development of vaccines and antiviral drugs are priorities...
April 24, 2018: Parasites & Vectors
Federico Alonso Zumaya-Estrada, María Carmen Rodríguez, Mario Henry Rodríguez
OBJECTIVE: To analyze the current knowledge of pathogen-insect interactions amenable for the design of molecular-based control strategies of vector-borne diseases. MATERIALS AND METHODS: We examined malaria, dengue, and Chagas disease pathogens and insect molecules that participate in interactions during their vectors infection. RESULTS: Pathogen molecules that participate in the insect intestine invasion and induced vector immune molecules are presented, and their inclusion in transmission blocking vaccines (TBV) and in genetically modify insect (GMI) vectors or symbiotic bacteria are discussed...
January 2018: Salud Pública de México
Daniela Loconsole, Angela Metallo, Anna Lisa De Robertis, Anna Morea, Michele Quarto, Maria Chironna
International travelers to areas endemic for vector-borne diseases (VBDs) may be at risk of contracting and spreading these diseases. The aim of this study was to evaluate the prevalence of immunoglobulin M (IgM) and immunoglobulin G (IgG) antibodies that are specific for Dengue Virus (DV), West Nile Virus (WNV), Chikungunya Virus (CHIKV), or Zika Virus (ZV) in a cohort of international travelers. The study enrolled travelers who attended the Travel Medicine and Migration outpatient service of Local Health Unit of Bari, Italy, in March 2015-June 2017 for counseling and vaccine prophylaxis before travel...
April 23, 2018: Vector Borne and Zoonotic Diseases
Gareth Iacobucci
No abstract text is available yet for this article.
April 20, 2018: BMJ: British Medical Journal
Stephan T Kudlacek, Lakshmanane Premkumar, Stefan W Metz, Ashutosh Tripathy, Andrey A Bobkov, Alexander Matthew Payne, Stephen Graham, James A Brackbill, Michael J Miley, Aravinda M de Silva, Brian Kuhlman
The spread of dengue (DENV) and Zika virus (ZIKV) is a major public health concern. The primary target of antibodies (Abs) that neutralize DENV and ZIKV is the envelope (E) glycoprotein, and there is interest in using soluble recombinant E (sRecE) proteins as subunit vaccines. However, the most potent neutralizing antibodies against DENV and ZIKV recognize epitopes on the virion surface that span two or more E proteins. Therefore, to create effective DENV and ZIKV vaccines, presentation of these quaternary epitopes may be necessary...
April 20, 2018: Journal of Biological Chemistry
Laura R H Ahlers, Alan G Goodman
Vector-borne diseases, including arboviruses, pose a serious threat to public health worldwide. Arboviruses of the flavivirus genus, such as Zika virus (ZIKV), dengue virus, yellow fever virus (YFV), and West Nile virus (WNV), are transmitted to humans from insect vectors and can cause serious disease. In 2017, over 2,000 reported cases of WNV virus infection occurred in the United States, with two-thirds of cases classified as neuroinvasive. WNV transmission cycles through two different animal populations: birds and mosquitoes...
2018: Frontiers in Cellular and Infection Microbiology
Gregg N Milligan, Mellodee White, Diana Zavala, Richard B Pyles, Vanessa V Sarathy, Alan D T Barrett, Nigel Bourne
Dengue is a mosquito-borne disease of global public health importance caused by four genetically and serologically related viruses (DENV-1 to DENV-4). Efforts to develop effective vaccines and therapeutics for dengue have been slowed by the paucity of preclinical models that mimic human disease. DENV-2 models in interferon receptor deficient AG129 mice were an important advance but only allowed testing against a single DENV serotype. We have developed complementary AG129 mouse models of severe disseminated dengue infection using strains of the other three DENV serotypes...
April 14, 2018: Antiviral Research
Sravanthi Vemireddy, Preethi Pallavi M C, Sampath Kumar Halmuthur M
Nasal vaccine delivery systems are emerging alternatives to the conventional sub unit vaccine delivery systems owing to their ability to stimulate potent antigen specific humoral and cellular immune responses. Additional virtue of nasal delivery is its close proximity of immune cells to external epithelial layer which is the route of entry to pathogens. Toxicity of emulsion based vaccine delivery systems may be attributed to the presence of high quantities of surfactants used for stabilizing the emulsions. A safer approach would be to reduce physiologically unwanted surfactant burden in the emulsion to the bare limit to necessity...
June 15, 2018: Carbohydrate Polymers
Teguh Hari Sucipto, Siti Churrotin, Harsasi Setyawati, Fahimah Martak, Kris Cahyo Mulyatno, Ilham Harlan Amarullah, Tomohiro Kotaki, Masanori Kameoka, Subagyo Yotopranoto, And Soegeng Soegijanto
Background: Dengue is a kind of infectious disease that was distributed in the tropical and sub-tropical areas. To date, there is no clinically approved dengue vaccine or antiviral for humans, even though there have been great efforts towards this end. Therefore, finding the effective compound against dengue virus (DENV) replication is very important. Among the complex compounds, copper(II)-imidazole derivatives are of interest because of their biological and medicinal benefits. Materials and Methods: In the present study, antiviral activity of [Cu(2,4,5-triphenylimidazole)2 ]n , was evaluated against different stages of dengue virus type 2 (DENV-2) replication in Vero cell using focus forming unit reduction assay and quantitative ELISA...
2018: African Journal of Infectious Diseases
Magelda Montoya, Matthew Collins, Wanwisa Dejnirattisai, Leah C Katzelnick, Henry Puerta-Guardo, Ramesh Jadi, Samuel Schildhauer, Piyada Supasa, Sirijitt Vasanawathana, Prida Malasit, Juthathip Mongkolsapaya, Aruna D de Silva, Hasitha Tissera, Angel Balmaseda, Gavin Screaton, Aravinda M de Silva, Eva Harris
Background: The four dengue virus serotypes (DENV1-4) and Zika virus (ZIKV) are related mosquito-borne flaviviruses of major importance globally. While monoclonal antibodies and plasma from DENV-immune donors can neutralize or enhance ZIKV in vitro and in small animal models, and vice versa, the extent, duration, and significance of cross-reactivity remains unknown, particularly in flavivirus-endemic regions. Methods: We studied neutralizing antibodies to ZIKV and DENV1-4 in longitudinal serologic specimens through 3 years post-infection from people in Latin America and Asia with laboratory-confirmed DENV infections...
April 2, 2018: Journal of Infectious Diseases
Jessica E Manning, David M Morens, Shaden Kamhawi, Jesus G Valenzuela, Matthew Memoli
Arthropod-borne viruses (arboviruses) are taxonomically diverse causes of significant morbidity and mortality. In recent decades, important mosquito-borne viruses such as West Nile, chikungunya, dengue, and Zika have re-emerged and spread widely, in some cases pandemically, to cause serious public health emergencies. There are no licensed vaccines against most of these viruses, and vaccine development and use has been complicated by the number of different viruses to protect against, by subtype and strain variation, and by the inability to predict when and where outbreaks will occur...
March 29, 2018: Journal of Infectious Diseases
Hercules Sakkas, Petros Bozidis, Ashley Franks, Chrissanthy Papadopoulou
Oropouche fever is an emerging zoonotic disease caused by Oropouche virus (OROV), an arthropod transmitted Orthobunyavirus circulating in South and Central America. During the last 60 years, more than 30 epidemics and over half a million clinical cases attributed to OROV infection have been reported in Brazil, Peru, Panama, Trinidad and Tobago. OROV fever is considered the second most frequent arboviral febrile disease in Brazil after dengue fever. OROV is transmitted through both urban and sylvatic transmission cycles, with the primary vector in the urban cycle being the anthropophilic biting midge Culicoides paraensis ...
April 4, 2018: Viruses
Stefan W Metz, Ashlie Thomas, Laura White, Mark Stoops, Markus Corten, Holger Hannemann, Aravinda M de Silva
BACKGROUND: The 4 dengue serotypes (DENV) are mosquito-borne pathogens that are associated with severe hemorrhagic disease. DENV particles have a lipid bilayer envelope that anchors two membrane glycoproteins prM and E. Two E-protein monomers form head-to-tail homodimers and three E-dimers align to form "rafts" that cover the viral surface. Some human antibodies that strongly neutralize DENV bind to quaternary structure epitopes displayed on E protein dimers or higher order structures forming the infectious virus...
April 2, 2018: Virology Journal
Gregory D Gromowski, Sandra Henein, Chandrika B Kannadka, David A Barvir, Stephen J Thomas, Aravinda M de Silva, Richard G Jarman
The dengue virus (DENV) vaccines that are licensed or in clinical development consist of DENV serotype 1-4 tetravalent formulations given simultaneously and are not acquired sequentially like natural infections. It is unclear what effect this has on development of protective levels of immunity to all four serotypes. Serotype-specific neutralizing antibody (NAb) is considered the most relevant correlate of protection from dengue disease. Here we assessed levels of serotype-specific and cross-reactive NAb in immune sera from 10 subjects vaccinated with a live attenuated tetravalent DENV vaccine developed at the Walter Reed Army Institute of Research...
March 27, 2018: Vaccine
Leah C Katzelnick, Eva Harris
In this review, we describe how longitudinal prospective community-based, school-based, and household-based cohort studies contribute to improving our knowledge of viral disease, focusing specifically on contributions to understanding and preventing dengue. We describe how longitudinal cohorts enable measurement of essential disease parameters and risk factors; provide insights into biological correlates of protection and disease risk; enable rapid application of novel biological and statistical technologies; lead to development of new interventions and inform vaccine trial design; serve as sentinels in outbreak conditions and facilitate development of critical diagnostic assays; enable holistic studies on disease in the context of other infections, comorbidities, and environmental risk factors; and build research capacity that strengthens national and global public health response and disease surveillance...
March 26, 2018: Current Opinion in Virology
Veronique Barban, Nathalie Mantel, Aymeric De Montfort, Anke Pagnon, Fabrine Pradezynski, Jean Lang, Florence Boudet
Recent data obtained with the live-attenuated tetravalent dengue CYD-TDV vaccine showed higher protective efficacy against DENV-4 compared with DENV-2. In contrast, results from earlier studies in non-human primates predicted comparable high levels of protection against each serotype. Maximum viral loads achieved in macaques by subcutaneous inoculation of DENV are generally much lower than those observed in naturally dengue-infected humans. This may contribute to overestimation of vaccine efficacy. Using more stringent DENV infection conditions consisting of intravenous inoculation of a 107 CCID50 dose in CYD-TDV-vaccinated macaques, complete protection (i...
March 28, 2018: Journal of Virology
Nor Azila Muhammad Azami, Meng Ling Moi, Yasushi Ami, Yuriko Suzaki, Chang-Kweng Lim, Satoshi Taniguchi, Masayuki Saijo, Tomohiko Takasaki, Ichiro Kurane
BACKGROUND: A vaccine against all four dengue virus (DENV) serotypes includes the formulation of one genotype of each serotype. Although genetic similarities among genotypes within a serotype are higher as compared to those among serotypes, differences in the immunogenicity of the included genotypes would be a critical issue in maximizing successful dengue vaccine development. Thus, we determined the neutralizing antibody responses against three genotypes of dengue virus serotype 2 (DENV-2), namely Cosmopolitan, Asian I, and Asian/American, after primary and secondary inoculation with DENV-2 in a dengue animal model, the common marmoset (Callithrix jacchus)...
March 27, 2018: Virology Journal
Hemalatha Beesetti, Poornima Tyagi, Brahmam Medapi, Vagolu Siva Krishna, Dharmarajan Sriram, Navin Khanna, Sathyamangalam Swaminathan
BACKGROUND: The global occurrence of dengue, a mosquito-borne viral disease caused by four distinct dengue viruses (DENV-1, -2, -3 and -4), is reported to have increased ~30-fold in the last fifty years, causing ~400 million infections a year. A limited use, sub-optimal live attenuated dengue vaccine has become available recently. It is becoming apparent that antibodies to DENVs can promote infection by Zika virus (ZIKV), a related mosquito-borne flavivirus. A drug to treat these flaviviral infections continues to be an unmet public health need...
March 27, 2018: Antiviral Therapy
Annelies Wilder-Smith
No abstract text is available yet for this article.
March 23, 2018: Clinical Microbiology and Infection
Jung-Seok Lee, José Lourenço, Sunetra Gupta, Andrew Farlow
BACKGROUND: The dengue vaccination era began when Dengvaxia (CYD-TDV) became available in 2016. In addition, several second-generation vaccine candidates are currently in phase 3 trials, suggesting that a broader availability of dengue vaccines may be possible in the near future. Advancing on the recent WHO-SAGE recommendations for the safe and effective use of CYD-TDV at the regional level on average, this study investigates the vaccination impacts and cost-effectiveness of CYD-TDV and of a hypothetical new vaccine candidate (NVC) in a country-specific manner for three endemic countries: Vietnam, Thailand, and Colombia...
March 21, 2018: Vaccine
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"